Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes

Abstract

To assess the revised World Health Organization-recommended dose of 10–20 mg/kg rifampicin (RMP), we studied the steady state pharmacokinetics of RMP in South African children who received standard treatment for drug-susceptible tuberculosis (TB)